Trial Profile
Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms PERMEATE
- 21 Mar 2018 Status changed from active, no longer recruiting to completed.
- 26 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 26 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.